Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
- PMID: 10802617
- DOI: 10.1038/75365
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
Abstract
Immunostimulatory DNA sequences (ISS) contain unmethylated CpG dinucleotides within a defined motif. Immunization with ISS-based vaccines has been shown to induce high antigen-specific cytotoxic lymphocyte (CTL) activity and a Th1-biased immune response. We have developed a novel ISS-based vaccine composed of ovalbumin (OVA) chemically conjugated to ISS-oligodeoxynucleotide (ODN). Protein-ISS conjugate (PIC) is more potent in priming CTL activity and Th1-biased immunity than other ISS-based vaccines. Cytotoxic lymphocyte activation by ISS-ODN-based vaccines is preserved in both CD4-/- and MHC class II-/- gene-deficient animals. Furthermore, PIC provides protection against a lethal burden of OVA-expressing tumor cells in a CD8+ cell-dependent manner. These results demonstrate that PIC acts through two unique mechanisms: T-helper-independent activation of CTL and facilitation of exogenous antigen presentation on MHC class I. This technology may have clinical applications in cancer therapy and in stimulating host defense in AIDS and chronic immunosuppression.
Comment in
-
Problem solving for tumor immunotherapy.Nat Biotechnol. 2000 May;18(5):491-2. doi: 10.1038/75343. Nat Biotechnol. 2000. PMID: 10802611 No abstract available.
Similar articles
-
The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.Int J Oncol. 2006 Apr;28(4):947-53. Int J Oncol. 2006. PMID: 16525645
-
Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.Immunol Lett. 2005 Jun 15;99(1):85-93. doi: 10.1016/j.imlet.2005.01.006. Epub 2005 Feb 16. Immunol Lett. 2005. PMID: 15894116
-
Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.Cancer Res. 2003 Nov 15;63(22):7920-5. Cancer Res. 2003. PMID: 14633722
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
-
Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.Adv Drug Deliv Rev. 2006 Oct 1;58(8):916-30. doi: 10.1016/j.addr.2005.11.003. Epub 2006 Aug 12. Adv Drug Deliv Rev. 2006. PMID: 16979788 Review.
Cited by
-
Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.Adv Healthc Mater. 2023 Jul;12(17):e2203028. doi: 10.1002/adhm.202203028. Epub 2023 Mar 1. Adv Healthc Mater. 2023. PMID: 36807733 Free PMC article.
-
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.J Immunol Res. 2015;2015:785634. doi: 10.1155/2015/785634. Epub 2015 Oct 25. J Immunol Res. 2015. PMID: 26583156 Free PMC article. Review.
-
Dendritic cell targeted vaccines: Recent progresses and challenges.Hum Vaccin Immunother. 2016 Mar 3;12(3):612-22. doi: 10.1080/21645515.2015.1105415. Hum Vaccin Immunother. 2016. PMID: 26513200 Free PMC article.
-
Delivery System of CpG Oligodeoxynucleotides through Eliciting an Effective T cell Immune Response against Melanoma in Mice.J Cancer. 2016 Jan 5;7(3):241-50. doi: 10.7150/jca.12899. eCollection 2016. J Cancer. 2016. PMID: 26918036 Free PMC article.
-
Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.Vaccine. 2007 Sep 28;25(39-40):6965-74. doi: 10.1016/j.vaccine.2007.06.063. Epub 2007 Jul 24. Vaccine. 2007. PMID: 17707958 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials